A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Roy M. Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y. Hua, Carol Cronenberger, Daniel Alvarez, Amy E. Bock, K. Lea Sewell

ABSTRACT

BACKGROUND: This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate adalimumab biosimilar, versus adalimumab reference product (Humira®) sourced from the EU (adalimumab-EU) in biologic-naïve patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) (10-25 mg/week). We report results for the first 26 weeks of treatment. METHODS: Patients with active RA (N = 597) were randomly assigned (1:1) to PF-06410293 or adalimumab-EU, while continuing with MTX treatment. The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 12. Therapeutic equivalence was concluded if the two-sided 95% confidence interval (CI) for the ACR20 difference between the two arms was entirely contained within the symmetric equivalence margin (±14%). Additionally, a two-sided 90% CI was calculated by using an asymmetric equivalence margin (-12%, 15%). Secondary efficacy endpoints to week 26 included ACR20/50/70, change from baseline Disease Activity Score based on high-sensitivity C-reactive protein [DAS28-4(CRP)], European League Against Rheumatism (EULAR) response, DAS28-4(CRP) of less than 2.6, and ACR/EULAR remission. QuantiFERON-TB testing was performed at screening and week 26. RESULTS: Patients (78.7% of whom were female and whose mean age was 52.5 years) had a mean baseline RA duration of 6.8 years. The mean baseline DAS28-4(CRP) values were 5.9 (PF-06410293) and 6.1 (adalimumab-EU). The observed week-12 ACR20 values were 68.7% (PF-06410293) and 72.7% (adalimumab-EU) in the intention-to-treat population. With non-responder imputation, the treatment difference in week-12 ACR20 was -2.98% and corresponding CIs-95% CI (-10.38%, 4.44%) and 90% CI (-9.25%, 3.28%)-were entirely contained within the equivalence margins (symmetric and asymmetric, respectively). The secondary efficacy endpoints were similar between arms. Over 26 weeks, injection-site reactions occurred in 1.7% versus 2.0%, hypersensitivity events in 4.4% versus 8.4%, pneumonia in 0.7% versus 2.0%, and opportunistic infections in 2.4% versus 1.7% in the PF-06410293 and adalimumab-EU arms, respectively. One death due to myocardial infarction occurred (adalimumab-EU arm). Rates of anti-drug antibody incidence were 44.4% (PF-06410293) and 50.5% (adalimumab-EU). CONCLUSIONS: The study results demonstrate that efficacy, safety, and immunogenicity of PF-06410293 and adalimumab-EU were similar during the first 26 weeks of treatment in patients with active RA on background MTX. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02480153 . First posted on June 24, 2015; EU Clinical Trials Register EudraCT number: 2014-000352-29 . Start date: October 27, 2014. More... »

PAGES

178

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-018-1676-y

DOI

http://dx.doi.org/10.1186/s13075-018-1676-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106151500

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30111357


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Southwestern Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.416214.4", 
          "name": [
            "Southwestern Medical Center, Metroplex Clinical Research Center, University of Texas, 8144 Walnut Hill Lane, Suite 810, 75231, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fleischmann", 
        "givenName": "Roy M.", 
        "id": "sg:person.01065106031.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charit\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Schlosspark-Klinik, University Medicine Berlin, Heubnerweg 2, 14059, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alten", 
        "givenName": "Rieke", 
        "id": "sg:person.0712065163.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712065163.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lithuanian University of Health Sciences", 
          "id": "https://www.grid.ac/institutes/grid.45083.3a", 
          "name": [
            "Department of Rheumatology, Hospital of Lithuanian University of Health Sciences, Eiveniu str.2, 50161, Kaunas, LT, Lithuania"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pileckyte", 
        "givenName": "Margarita", 
        "id": "sg:person.01202271707.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202271707.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc., 500 Arcola Road Collegeville, 19426, Collegeville, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lobello", 
        "givenName": "Kasia", 
        "id": "sg:person.0606360255.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606360255.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc., 10777 Science Center Drive, CB1/2103, 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hua", 
        "givenName": "Steven Y.", 
        "id": "sg:person.01226203522.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226203522.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc., 500 Arcola Road Collegeville, 19426, Collegeville, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cronenberger", 
        "givenName": "Carol", 
        "id": "sg:person.0654253230.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654253230.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc., 500 Arcola Road Collegeville, 19426, Collegeville, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alvarez", 
        "givenName": "Daniel", 
        "id": "sg:person.0743707423.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743707423.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc., 300 Technology Square, 02139, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bock", 
        "givenName": "Amy E.", 
        "id": "sg:person.015465642640.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015465642640.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc., 300 Technology Square, 02139, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sewell", 
        "givenName": "K. Lea", 
        "id": "sg:person.01254360105.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254360105.70"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1208/s12248-014-9599-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008471779", 
          "https://doi.org/10.1208/s12248-014-9599-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.1780380602", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017539871"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.27584", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018685765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.27584", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018685765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1479-8077.2007.00248.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020677099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0929-6646(09)60071-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025663563"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.4780040211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026299215"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2013-204920", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028762450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.10697", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044317192"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.20217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048024686"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2011.05.044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049020799"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.21519", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049214196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.21519", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049214196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.japh.2017.05.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090379371"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate adalimumab biosimilar, versus adalimumab reference product (Humira\u00ae) sourced from the EU (adalimumab-EU) in biologic-na\u00efve patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) (10-25 mg/week). We report results for the first 26 weeks of treatment.\nMETHODS: Patients with active RA (N = 597) were randomly assigned (1:1) to PF-06410293 or adalimumab-EU, while continuing with MTX treatment. The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 12. Therapeutic equivalence was concluded if the two-sided 95% confidence interval (CI) for the ACR20 difference between the two arms was entirely contained within the symmetric equivalence margin (\u00b114%). Additionally, a two-sided 90% CI was calculated by using an asymmetric equivalence margin (-12%, 15%). Secondary efficacy endpoints to week 26 included ACR20/50/70, change from baseline Disease Activity Score based on high-sensitivity C-reactive protein [DAS28-4(CRP)], European League Against Rheumatism (EULAR) response, DAS28-4(CRP) of less than\u20092.6, and ACR/EULAR remission. QuantiFERON-TB testing was performed at screening and week 26.\nRESULTS: Patients (78.7% of whom were female and whose mean age was 52.5 years) had a mean baseline RA duration of 6.8 years. The mean baseline DAS28-4(CRP) values were 5.9 (PF-06410293) and 6.1 (adalimumab-EU). The observed week-12 ACR20 values were 68.7% (PF-06410293) and 72.7% (adalimumab-EU) in the intention-to-treat population. With non-responder imputation, the treatment difference in week-12 ACR20 was -2.98% and corresponding CIs-95% CI (-10.38%, 4.44%) and 90% CI (-9.25%, 3.28%)-were entirely contained within the equivalence margins (symmetric and asymmetric, respectively). The secondary efficacy endpoints were similar between arms. Over 26 weeks, injection-site reactions occurred in 1.7% versus 2.0%, hypersensitivity events in 4.4% versus 8.4%, pneumonia in 0.7% versus 2.0%, and opportunistic infections in 2.4% versus 1.7% in the PF-06410293 and adalimumab-EU arms, respectively. One death due to myocardial infarction occurred (adalimumab-EU arm). Rates of anti-drug antibody incidence were 44.4% (PF-06410293) and 50.5% (adalimumab-EU).\nCONCLUSIONS: The study results demonstrate that efficacy, safety, and immunogenicity of PF-06410293 and adalimumab-EU were similar during the first 26 weeks of treatment in patients with active RA on background MTX.\nTRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02480153 . First posted on June 24, 2015; EU Clinical Trials Register EudraCT number: 2014-000352-29 . Start date: October 27, 2014.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13075-018-1676-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira\u00ae) in the treatment of active rheumatoid arthritis", 
    "pagination": "178", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "73b909aafb420da516266036ce972bbffcda7e2806505e87129cb2eaddc8a7ea"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30111357"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-018-1676-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106151500"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-018-1676-y", 
      "https://app.dimensions.ai/details/publication/pub.1106151500"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000572.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13075-018-1676-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-018-1676-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-018-1676-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-018-1676-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-018-1676-y'


 

This table displays all metadata directly associated to this object as RDF triples.

173 TRIPLES      21 PREDICATES      41 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-018-1676-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N9faac64feec041e0917d532e14eb82d0
4 schema:citation sg:pub.10.1208/s12248-014-9599-2
5 https://doi.org/10.1002/art.10697
6 https://doi.org/10.1002/art.1780380602
7 https://doi.org/10.1002/art.20217
8 https://doi.org/10.1002/art.21519
9 https://doi.org/10.1002/art.27584
10 https://doi.org/10.1002/sim.4780040211
11 https://doi.org/10.1016/j.clinthera.2011.05.044
12 https://doi.org/10.1016/j.japh.2017.05.014
13 https://doi.org/10.1016/s0929-6646(09)60071-1
14 https://doi.org/10.1111/j.1479-8077.2007.00248.x
15 https://doi.org/10.1136/annrheumdis-2013-204920
16 schema:datePublished 2018-12
17 schema:datePublishedReg 2018-12-01
18 schema:description BACKGROUND: This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate adalimumab biosimilar, versus adalimumab reference product (Humira®) sourced from the EU (adalimumab-EU) in biologic-naïve patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) (10-25 mg/week). We report results for the first 26 weeks of treatment. METHODS: Patients with active RA (N = 597) were randomly assigned (1:1) to PF-06410293 or adalimumab-EU, while continuing with MTX treatment. The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 12. Therapeutic equivalence was concluded if the two-sided 95% confidence interval (CI) for the ACR20 difference between the two arms was entirely contained within the symmetric equivalence margin (±14%). Additionally, a two-sided 90% CI was calculated by using an asymmetric equivalence margin (-12%, 15%). Secondary efficacy endpoints to week 26 included ACR20/50/70, change from baseline Disease Activity Score based on high-sensitivity C-reactive protein [DAS28-4(CRP)], European League Against Rheumatism (EULAR) response, DAS28-4(CRP) of less than 2.6, and ACR/EULAR remission. QuantiFERON-TB testing was performed at screening and week 26. RESULTS: Patients (78.7% of whom were female and whose mean age was 52.5 years) had a mean baseline RA duration of 6.8 years. The mean baseline DAS28-4(CRP) values were 5.9 (PF-06410293) and 6.1 (adalimumab-EU). The observed week-12 ACR20 values were 68.7% (PF-06410293) and 72.7% (adalimumab-EU) in the intention-to-treat population. With non-responder imputation, the treatment difference in week-12 ACR20 was -2.98% and corresponding CIs-95% CI (-10.38%, 4.44%) and 90% CI (-9.25%, 3.28%)-were entirely contained within the equivalence margins (symmetric and asymmetric, respectively). The secondary efficacy endpoints were similar between arms. Over 26 weeks, injection-site reactions occurred in 1.7% versus 2.0%, hypersensitivity events in 4.4% versus 8.4%, pneumonia in 0.7% versus 2.0%, and opportunistic infections in 2.4% versus 1.7% in the PF-06410293 and adalimumab-EU arms, respectively. One death due to myocardial infarction occurred (adalimumab-EU arm). Rates of anti-drug antibody incidence were 44.4% (PF-06410293) and 50.5% (adalimumab-EU). CONCLUSIONS: The study results demonstrate that efficacy, safety, and immunogenicity of PF-06410293 and adalimumab-EU were similar during the first 26 weeks of treatment in patients with active RA on background MTX. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02480153 . First posted on June 24, 2015; EU Clinical Trials Register EudraCT number: 2014-000352-29 . Start date: October 27, 2014.
19 schema:genre research_article
20 schema:inLanguage en
21 schema:isAccessibleForFree true
22 schema:isPartOf N91287203373247079123742bb23210ee
23 Na244e89647f44231a7ce1631c76f1f7d
24 sg:journal.1297499
25 schema:name A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
26 schema:pagination 178
27 schema:productId N2c282ad946eb4d5cbde812ba7959d69c
28 N71e8e49ccd1e4b5b98359dce1dcecc2c
29 N8bf5427f50da49149ce78c44893fcead
30 Nb4ffd82c973246bfbed7c8152ca512ba
31 Ndcb1ccd994f74bdc8a42e4d53fef16ee
32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106151500
33 https://doi.org/10.1186/s13075-018-1676-y
34 schema:sdDatePublished 2019-04-10T16:51
35 schema:sdLicense https://scigraph.springernature.com/explorer/license/
36 schema:sdPublisher Nddd784fdee584652bba5eeed25d4e7ca
37 schema:url https://link.springer.com/10.1186%2Fs13075-018-1676-y
38 sgo:license sg:explorer/license/
39 sgo:sdDataset articles
40 rdf:type schema:ScholarlyArticle
41 N0fe8dc6472a44321b99faeac9ca7d5f1 rdf:first sg:person.01254360105.70
42 rdf:rest rdf:nil
43 N2c282ad946eb4d5cbde812ba7959d69c schema:name doi
44 schema:value 10.1186/s13075-018-1676-y
45 rdf:type schema:PropertyValue
46 N5e41c8530ade440fa04db673ed7a77a4 rdf:first sg:person.01226203522.02
47 rdf:rest Nac9dc9f7f0fb4abe8d9ded7e0356085b
48 N71e8e49ccd1e4b5b98359dce1dcecc2c schema:name dimensions_id
49 schema:value pub.1106151500
50 rdf:type schema:PropertyValue
51 N8bf5427f50da49149ce78c44893fcead schema:name nlm_unique_id
52 schema:value 101154438
53 rdf:type schema:PropertyValue
54 N8d77bce6d64044a7b3265f54b62e6b14 rdf:first sg:person.0712065163.41
55 rdf:rest Ndb2facee452c45f3819bc0991c94693d
56 N91287203373247079123742bb23210ee schema:issueNumber 1
57 rdf:type schema:PublicationIssue
58 N9faac64feec041e0917d532e14eb82d0 rdf:first sg:person.01065106031.43
59 rdf:rest N8d77bce6d64044a7b3265f54b62e6b14
60 Na244e89647f44231a7ce1631c76f1f7d schema:volumeNumber 20
61 rdf:type schema:PublicationVolume
62 Nac9dc9f7f0fb4abe8d9ded7e0356085b rdf:first sg:person.0654253230.57
63 rdf:rest Nfb0aca4d8d194ea5a21f51887cb08ec5
64 Nb4ffd82c973246bfbed7c8152ca512ba schema:name pubmed_id
65 schema:value 30111357
66 rdf:type schema:PropertyValue
67 Ndb2facee452c45f3819bc0991c94693d rdf:first sg:person.01202271707.53
68 rdf:rest Nf08b7382edfa44ee9dab86b80fb38e56
69 Ndcb1ccd994f74bdc8a42e4d53fef16ee schema:name readcube_id
70 schema:value 73b909aafb420da516266036ce972bbffcda7e2806505e87129cb2eaddc8a7ea
71 rdf:type schema:PropertyValue
72 Nddd784fdee584652bba5eeed25d4e7ca schema:name Springer Nature - SN SciGraph project
73 rdf:type schema:Organization
74 Ne04f28dd261d4d63959aa2a5c3b961b1 rdf:first sg:person.015465642640.49
75 rdf:rest N0fe8dc6472a44321b99faeac9ca7d5f1
76 Nf08b7382edfa44ee9dab86b80fb38e56 rdf:first sg:person.0606360255.36
77 rdf:rest N5e41c8530ade440fa04db673ed7a77a4
78 Nfb0aca4d8d194ea5a21f51887cb08ec5 rdf:first sg:person.0743707423.54
79 rdf:rest Ne04f28dd261d4d63959aa2a5c3b961b1
80 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
81 schema:name Medical and Health Sciences
82 rdf:type schema:DefinedTerm
83 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
84 schema:name Clinical Sciences
85 rdf:type schema:DefinedTerm
86 sg:journal.1297499 schema:issn 1478-6354
87 1478-6362
88 schema:name Arthritis Research & Therapy
89 rdf:type schema:Periodical
90 sg:person.01065106031.43 schema:affiliation https://www.grid.ac/institutes/grid.416214.4
91 schema:familyName Fleischmann
92 schema:givenName Roy M.
93 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43
94 rdf:type schema:Person
95 sg:person.01202271707.53 schema:affiliation https://www.grid.ac/institutes/grid.45083.3a
96 schema:familyName Pileckyte
97 schema:givenName Margarita
98 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202271707.53
99 rdf:type schema:Person
100 sg:person.01226203522.02 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
101 schema:familyName Hua
102 schema:givenName Steven Y.
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226203522.02
104 rdf:type schema:Person
105 sg:person.01254360105.70 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
106 schema:familyName Sewell
107 schema:givenName K. Lea
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254360105.70
109 rdf:type schema:Person
110 sg:person.015465642640.49 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
111 schema:familyName Bock
112 schema:givenName Amy E.
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015465642640.49
114 rdf:type schema:Person
115 sg:person.0606360255.36 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
116 schema:familyName Lobello
117 schema:givenName Kasia
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606360255.36
119 rdf:type schema:Person
120 sg:person.0654253230.57 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
121 schema:familyName Cronenberger
122 schema:givenName Carol
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654253230.57
124 rdf:type schema:Person
125 sg:person.0712065163.41 schema:affiliation https://www.grid.ac/institutes/grid.6363.0
126 schema:familyName Alten
127 schema:givenName Rieke
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712065163.41
129 rdf:type schema:Person
130 sg:person.0743707423.54 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
131 schema:familyName Alvarez
132 schema:givenName Daniel
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743707423.54
134 rdf:type schema:Person
135 sg:pub.10.1208/s12248-014-9599-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008471779
136 https://doi.org/10.1208/s12248-014-9599-2
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1002/art.10697 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044317192
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1002/art.1780380602 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017539871
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1002/art.20217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048024686
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1002/art.21519 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049214196
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1002/art.27584 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018685765
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1002/sim.4780040211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026299215
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/j.clinthera.2011.05.044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049020799
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1016/j.japh.2017.05.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090379371
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/s0929-6646(09)60071-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025663563
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1111/j.1479-8077.2007.00248.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1020677099
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1136/annrheumdis-2013-204920 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028762450
159 rdf:type schema:CreativeWork
160 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
161 schema:name Pfizer Inc., 10777 Science Center Drive, CB1/2103, 92121, San Diego, CA, USA
162 Pfizer Inc., 300 Technology Square, 02139, Cambridge, MA, USA
163 Pfizer Inc., 500 Arcola Road Collegeville, 19426, Collegeville, PA, USA
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.416214.4 schema:alternateName Southwestern Medical Center
166 schema:name Southwestern Medical Center, Metroplex Clinical Research Center, University of Texas, 8144 Walnut Hill Lane, Suite 810, 75231, Dallas, TX, USA
167 rdf:type schema:Organization
168 https://www.grid.ac/institutes/grid.45083.3a schema:alternateName Lithuanian University of Health Sciences
169 schema:name Department of Rheumatology, Hospital of Lithuanian University of Health Sciences, Eiveniu str.2, 50161, Kaunas, LT, Lithuania
170 rdf:type schema:Organization
171 https://www.grid.ac/institutes/grid.6363.0 schema:alternateName Charité
172 schema:name Schlosspark-Klinik, University Medicine Berlin, Heubnerweg 2, 14059, Berlin, Germany
173 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...